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Genome-wide analyses reveal a 
highly conserved Dengue virus 
envelope peptide which is critical 
for virus viability and antigenic in 
humans
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Targeting regions of proteins that show a high degree of structural conservation has been proposed as 
a method of developing immunotherapies and vaccines that may bypass the wide genetic variability 
of RNA viruses. Despite several attempts, a vaccine that protects evenly against the four circulating 
Dengue virus (DV) serotypes remains elusive. To find critical conserved amino acids in dengue viruses, 
120 complete genomes of each serotype were selected at random and used to calculate conservation 
scores for nucleotide and amino acid sequences. The identified peptide sequences were analysed for 
their structural conservation and localisation using crystallographic data. The longest, surface exposed, 
highly conserved peptide of Envelope protein was found to correspond to amino acid residues 250 to 
270. Mutation of this peptide in DV1 was lethal, since no replication of the mutant virus was detected in 
human cells. Antibodies against this peptide were detected in DV naturally infected patients indicating 
its potential antigenicity. Hence, this study has identified a highly conserved, critical peptide in DV that 
is a target of antibodies in infected humans.
Dengue is a mosquito-borne disease caused by a group of viruses collectively known as Dengue virus, belonging 
to the Flaviviridae family. It affects nearly 390 million people every year worldwide1 with symptoms ranging from 
mild fever to severe shock syndrome. Although recently different vaccination strategies have achieved reasonable 
levels of protection, a vaccine that protects uniformly against the circulating serotypes is not available2. This is 
partly due to the high variability among these viruses, which can lead to partially protective immune responses 
and antibody dependent enhancement (ADE) of infection when non-neutralising antibodies facilitate virus entry 
by Fc gamma receptors3–6.
Dengue viruses (DV) are enveloped, ssRNA viruses with a single open reading frame encoding three struc-
tural and seven non-structural proteins7. The genetic variance amongst DV results in diverse immune responses 
such that they are classified into four serogroups (DV1–4) based on antigenic diversity8,9. Although mutations 
occur randomly in the genome, viral proteins show a combination of regions that are permissive to multiple 
mutations, which enable immune evasion through antigenic variation, and regions where amino acid residues 
critical for structure and viral fitness are conserved10. In general, regions exposed to the immune system are prone 
to variation, however, even the envelope (E) protein, the main antigenic determinant on the virion, retains highly 
conserved cryptic peptides10,11. It has been demonstrated that those conserved regions in structural proteins have 
an important role in viral fitness and might be targets of broadly neutralising antibodies in viruses such as HIV 
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and Influenza A virus. For instance, although the majority of the protective immune response against influenza 
virus is provided by antibodies against the head of haemagglutinin (HA), new classes of multi-neutralising anti-
bodies have been isolated that target the highly conserved HA stalk region12–17. Antibodies with similar properties 
have also been found that target functionally conserved regions of HIV glycoprotein 12018–22. In both cases these 
regions are being evaluated as vaccine targets and the antibodies elicited have been used to study immunoprophy-
laxis strategies.
In this context, the sequence conservation of DV was evaluated, with the aim of identifying conserved regions 
in the E protein. All complete genome sequences available on access date for DV4 in NCBI (120 sequences) 
were analysed along with the same number of genomes for each other DV serotype, that were randomly selected 
through their NCBI sorting numbers (access on November, 26, 2013). This unbiased dataset, comprising 480 
sequences (all sequence IDs in Supplementary Data) allowed ample representation of the known variability 
observed in this taxonomic unit. The 480 GenBank files obtained in the previous step were processed using 
custom PERL scripts written using BioPerl module23 to extract protein and coding sequences. MUSCLE software 
was then used to align protein sequences with default parameters and these alignments, together with CDS data, 
were used to create a codon alignment. For both protein and codon alignments conservation scores were calcu-
lated based on the ratio of the count for the most frequent character (amino acids or nucleotides plus gaps) at a 
given position and the total number of sequences evaluated (480). To detect local conserved regions the fitting 
of a smooth curve to protein and codon conservation score data was carried out using smooth.spline function 
implemented in R language with smoothing parameter set to 0.4. The conservation scores varied from 0.4 to 1 
(scores for all peptides are available in Supplementary Table), where a score closer to 1 corresponds to a higher 
conservation of the region across all analysed sequences (Fig. 1a). Although structural proteins are more variable 
in general, some regions in E demonstrated to be conserved as the non-structural proteins average. To analyse the 
E protein with greater resolution we repeated this procedure with its sequences separated from the full genome. 
This revealed two main peaks of conservation on the envelope protein (Fig. 1b). Further analyses revealed that 
the first of these sites is the fusion peptide. This peptide was first described in 1989, comprises a hydrophobic loop 
highly conserved in all flaviviruses, that is normally buried at the E dimeric form and becomes exposed at the tip 
of the fusogenic trimer (Fig. 2a,b)24–26. The second most significant peak of conservation was also mapped into 
domain II of the E protein and comprised residues 250–270 (polyprotein residues 530–551). Internally located 
in pre-fusion E dimer, covering the final residues of the ij loop, the α B helix and the beginning of the kl loop, the 
structure of this peptide (from now E250–270) was visualised using available structures of DV E proteins in pre- and 
post-fusion forms (Fig. 2a,b). E250–270 is the longest conserved peptide that is solvent-exposed in the E protein 
trimer, which is responsible for fusion of the viral envelope to the host membrane (Fig. 2b). Comparison of the 
localisation and structure of this DV peptide with those of other flavivirus E proteins shows its cross-species 
conservation (Fig. 2a,b). To visualise this conservation at the amino-acid sequence level, WebLogo was used27 to 
create a representation for the region spanning the peptide (columns 530–551). WebLogo was run using stand-
ard parameters and considering equiprobable amino acid frequencies. The same strategy was employed to com-
pare the conservation of E250–270 in other flaviviruses. 120 sequences of Japanese encephalitis virus (JEV), 120 of 
Tick-borne encephalitis virus (TBEV), 120 of West Nile virus (WNV), were selected randomly from GenBank as 
well as the 70 sequences of Yellow fever virus (YFV) and 63 of Zika virus (ZKV), available, aligned with MUSCLE 
and visualized all together with WebLogo. Sixteen out of 21 amino acids in this peptide were 100% conserved in 
every DV sequence evaluated, being DV4 the most divergent among the four serotypes. When compared to other 
Flaviviruses at least seven amino acids from E250–270 are highly conserved (V250, L253, G254, Q256, G258, L264, 
G266; Fig. 2c and Supplementary Figure). These data indicate that E250–270 is conserved both at the sequence and 
structural levels across multiple flaviviruses.
As there is no specific reported function associated with the region where E250–270 is located in DV, to establish 
the significance of this highly conserved peptide, a DV was generated with a mutated E250–270 peptide (Fig. 3a). 
Several hydrophobic side chains were removed by mutation of five amino acid residues to alanine. These changes 
were designed to remove some of the most conserved side chains across all E protein sequences whilst minimising 
structural disruption across the peptide. Prediction of the effect of these substitutions on the three-dimensional 
structure of the envelope protein was carried out with Modeller28 using the complete E protein x-ray crystallo-
graphic structure as a template29 (Fig. 3b). PROCHECK30, WHAT IF31 and Verify3D32 algorithms were used to 
ensure the satisfaction of stereochemical restraints indicating that the amino acid substitutions could be tolerated 
by the E protein without gross structural disruption. More studies will be necessary to fully evaluate the impact 
of these mutations on E protein biology.
An infectious clone of DV1, strain BR/90, was used to construct the mutant virus33. Firstly, three silent nucleo-
tide changes were inserted to add restriction enzyme cleavage sites (C368T, T1663G, G1822C, based on GenBank 
AF226685.2) and then alanine substitutions were introduced in E protein amino acids 250–253 and 255 by gene 
synthesis and conventional cloning (Fig. 3a). The resultant infectious clone, named Conserved Surface Mutant 
1 (CSMut1), was fully sequenced and no modifications other than those desired were observed. CSMut1 and 
matching wild type (WT) were in vitro transcribed using MegaScript T7 synthesis kit (Ambion), supplemented 
with m7G(5′ )ppp(5′ )G RNA Cap Structure Analog (New England Biolabs). RNA was purified (RNeasy Mini 
Kit, Qiagen), and transfected into Huh7.5 cells with Lipofectin (Invitrogen). Cells and supernatant were recov-
ered at indicated hours post transfection (h.p.t.) and the RNA extracted using RNeasy Mini Kit or QIAamp 
Viral RNA Mini Kit, respectively (both Qiagen). Using RT-qPCR for non-structural protein 5 (NS5) mRNA 
(5′ GCAAACATCTTCAGGGGAAGT 3′ , 5′ GCTCCCGTACCTCTCCTACC 3′ ), only decreasing quantities of 
CSMut1 NS5 transcript were observed in both cell associated RNA or culture supernatant, suggesting an impaired 
ability of this mutant virus to replicate (Fig. 3c). The WT virus, on the other hand retained detectable levels of 
cell-associated DV RNA and increasing amounts of DV RNA in the culture supernatant consistent with efficient 
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replication with the expected kinetics for this virus (Fig. 3c). Furthermore, CSMut1 growth was not detected by 
plaque assay (data not shown).
The impact of CSMut1 on DV1 was also assessed by immunofluorescence for the viral envelope antigen in 
Huh7.5 cells34. Briefly, Huh7.5 cells were transfected with wild type or CSMut1 RNA using Lipofectin, fixed 
after 120 hours, and stained with monoclonal anti-E antibody (4G2 - ATCC® HB-112™), using Alexa Fluor 488 
rabbit anti-mouse IgG (H + L, Life Technologies) as a secondary antibody, and DAPI counter stain (Molecular 
Probes). In agreement with RNA detection (Fig. 3c), E protein expression was not observed in cells transfected 
with CSMut1 RNA, suggesting that the mutant virus was not able to spread in Huh7.5 cells (Fig. 3d). To under-
stand whether the impairment caused by CSMut1 was restricted to the mammalian host, similar experiments to 
those described above were performed in a C6/36 Aedes albopictus cell line. The results were remarkably similar 
to those in human cells (data not shown), suggesting that the defect caused by the mutations were not due to a 
host specific factor.
These data show that, despite the great diversity among the serotypes of dengue viruses there are at least two 
polypeptides within its main antigenic determinant that are highly conserved at both the sequence and structural 
levels. These two regions were also reported during analysis of pan-DV sequences as potential immune-relevant 
Figure 1. Genome-wide analysis of DV conserved sites. Conservation profile of nucleotides (red line) and 
amino acids (black line) of 480 dengue coding sequences (CDS) (a) and their respective envelope proteins (b). The 
“x” axis represents the position of amino acid residues in the DV CDS (a) or Envelope protein (b) and “y” axis 
represents the conservation score, where 1 indicates the highest conservation. The two most highly conserved 
peptides in the envelope protein (b) are the fusion peptide (residues E99–112, highlighted in the blue box) and 
E250–270 (red box). Above “a” the schematic DV CDS. C: capsid; prM: membrane precursor; E: envelope; NS: 
non-structural. Above “b” the scheme of E protein domains (I, II, II), the stem segment and transmembrane 
anchor (TM).
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T cell determinants11. These peptides are generally buried in dimeric E form, and are thought to become fully 
exposed only in the E fusogenic form of mature virion35. This assumption suggests that once hidden to the 
humoral immune response, these regions remain conserved due to the absence of selective pressure from host 
immunity. To test this, the presence of antibodies against E250–270 was assessed in patient sera. Serum samples 
Figure 2. E250–270 sequence and structural conservation in different flaviviruses. (a) The fusion peptide  
(in blue) and E250–270 (in red) are highlighted in envelope monomer structures of DV1, JEV and ZKV and (b) in 
the trimeric form of DV1 and TBEV. PDB ids: 4GSX, 3P54, 5JHM and 1URZ. (c) WebLogo schematic showing 
the amino acid composition per site in E250–270 of DV and other flavivirus. Polar amino acids (G,S,T,Y,C) 
are colored in green, neutral (Q,N) in purple, basic (K,R,H) in blue, acidic (D,E) in red and hydrophobic 
(A,V,L,I,P,W,F,M) in black.
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were obtained from an outbreak in Paraná state, Brazil (2013) according to the approved guidelines of Fiocruz 
(Fundação Oswaldo Cruz), within Instituto Carlos Chagas (Curitiba, Brazil). Experiments involving human sub-
jects were approved by the committee of ethics and research (Comitê de Ética e Pesquisa – CEP) of Fiocruz-RJ 
under protocol 617/11. Informed consent was obtained from all donors. 70 serum samples were evaluated for DV 
infection (by NS1, IgM and IgG ELISAs). Samples corresponded to 54 DV1 sera designated positive by at least 
one assay and from patients in the acute phase of disease (up to the seventh day after the onset of symptoms) and 
16 control sera from non-infected individuals. An indirect ELISA protocol was used to identify anti-E250–270 IgG 
antibodies36 (Fig. 4). Briefly, plates were coated with synthetic E253–270 peptide (it was not possible to solubilise a 
full length E250–270 peptide), blocked and incubated with serum samples. An HRP-linked, goat anti-human IgG 
(H + L, Invitrogen) was used as secondary antibody, and the plates were treated with o-phenylenediamine in 
citrate phosphate buffer containing 30% hydrogen peroxide. These ELISA data demonstrated this peptide to be 
antigenic in human natural infections, despite its predicted buried nature in the dimeric E form. One explanation 
for the development of antibodies to this site would be the dynamic movement of the virus particle, described 
Figure 3. CSMut1 design, modelling and infectivity. (a) The wild type E250–270 and CSMut1 sequences are 
shown with mutated amino acids highlighted in red. (b) Wild type (on the left) and CSMut1 model (on the 
right) with E250–270 in red. (c) Relative quantification of DV NS5 RNA in Huh7.5 cells transfected with wild type 
and CSMut1 genomes at different time points. Cell associated RNA is shown in the left panel and supernatant 
extracted RNA in the right panel. (d) DV E-protein immunofluorescence staining of WT and CSMut1 120 hours 
after genome transfection in Huh7.5 cells (bars correspond to 32 μ M).
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as ‘breathing’37,38. In agreement, Ramanathan, B. et al.39 predict the peptide as being a potential linear epitope, 
and the Rey group described a broadly neutralising monoclonal antibody that interacts with the first valine of 
E250–27040. Therefore, two other reasons for conservation could be explored i) structure and ii) function. Modelling 
of the mutant E protein did not show evidence of structure destabilisation, even though the mutated residues were 
conserved across almost all analysed virus sequences, suggesting that E250–270 might have a functional role in the 
DV life cycle. In agreement with our data other groups suggest that amino acids within this region are key to the 
E protein biology. Accordingly, a single substitution at V251A moderately restricts DV replication and viral par-
ticle production in C6/36 and Vero cells, and reduces viral E protein detection by immunofluorescence in C6/36 
and BHK-21 transfected cells41. Moreover, it was demonstrated that G266 and I270 substitutions to tryptophan 
affected viral replication in mammals and insect cells, and the I270W reduced fusion42. In contrast the study of 
Christian et al. using replicons with random point mutations in E protein did not verify significant differences in 
E expression, budding and infectivity when mutating residues of the peptide´s N-terminus (such as V251, and 
others mutated in CSMut1), or residues 266 and 27043. This could be related due to the amino acid utilized in sub-
stitutions, restrictions of the replicon´s method, and the contribution of multiple mutations as present in CSMut1. 
On the other hand, they suggests that other residues in peptide´s C-terminus, M258, H259 and A265, could have 
important role in fusion and, if mutated, greatly reduce or practically abolish viral replication43. These residues 
could form latch contacts with M proteins preventing the premature triggering of E protein. M258 forms with 
other residues a hydrophobic path that appears to be important to interact with F400 of E stem region in DV1 
trimer, and histidine protonation, among them H259, enable the dissociation of E and M protein contacts29,43. The 
undetectable level of replication observed to CSMut1 demonstrated the importance of E250–270 to viral infectivity 
and further investigations should be done to elucidate the exact function this conserved peptide. Moreover the 
detection of antibodies anti E250–270 in natural infected patients point the possibility to the use of these peptide as 
immunological target, as recently shown36.
Our strategy enables identification of the most conserved regions in DV genomes, other flavivirus such as 
ZKV, and also the rational designing of mutant viruses to investigate the importance of these regions in viral 
fitness and infectivity. As carried out for E250–270 peptide, a systematic analysis of other highly conserved regions 
could suggest potential immunological/pharmacologic target for dengue treatment and control. Moreover, these 
knowledge can be extrapolated for other ssRNA genome viruses, and contribute to understand the evolution of 
their cryptic conserved peptides.
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